InMed Pharmaceuticals Inc. (NASDAQ:INM) Short Interest Update

InMed Pharmaceuticals Inc. (NASDAQ:INM) was the target of a large drop in short interest in March. As of March 15th, there was short interest totalling 21,700 shares, a drop of 19.3% from the February 28th total of 26,900 shares. Based on an average daily volume of 458,500 shares, the short-interest ratio is currently 0.0 days. Approximately 3.1% of the shares of the stock are short sold.

InMed Pharmaceuticals Price Performance

Shares of InMed Pharmaceuticals stock traded up $0.04 during trading on Tuesday, hitting $2.11. 20,400 shares of the company were exchanged, compared to its average volume of 227,110. InMed Pharmaceuticals has a fifty-two week low of $2.01 and a fifty-two week high of $15.70. The company has a quick ratio of 2.44, a current ratio of 3.05 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average price of $3.06 and a 200 day moving average price of $4.19. The stock has a market capitalization of $2.55 million, a price-to-earnings ratio of -0.15 and a beta of 0.18.

InMed Pharmaceuticals (NASDAQ:INM) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($3.64) earnings per share for the quarter. InMed Pharmaceuticals had a negative net margin of 163.75% and a negative return on equity of 90.74%.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.